Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U2DO
|
|||
| Former ID |
DIB016180
|
|||
| Drug Name |
FP-1039
|
|||
| Synonyms |
FPT-039; HGS-1036; Modified growth factor receptor (cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv,cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics/ Human Genome Sciences
Click to Show/Hide
|
|||
| Indication | Endometrial cancer [ICD-11: 2C76; ICD-9: 182] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-9: 140-199, 210-229] | Phase 1b | [2] | ||
| Company |
FivePrime Therapeutics Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fibroblast growth factor receptor 1 (FGFR1) | Target Info | Antagonist | [3] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Adherens junction | ||||
| Signaling pathways regulating pluripotency of stem cells | ||||
| Regulation of actin cytoskeleton | ||||
| Pathways in cancer | ||||
| Proteoglycans in cancer | ||||
| Prostate cancer | ||||
| Melanoma | ||||
| Central carbon metabolism in cancer | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Angiogenesis | |||
| FGF signaling pathway | ||||
| Pathway Interaction Database | Glypican 1 network | |||
| Syndecan-4-mediated signaling events | ||||
| N-cadherin signaling events | ||||
| FGF signaling pathway | ||||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Endochondral Ossification | ||||
| MAPK Signaling Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Hair Follicle Development: Induction (Part 1 of 3) | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Signaling Pathways in Glioblastoma | ||||
| Neural Crest Differentiation | ||||
| Signaling by FGFR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01244438) Study of FP-1039 in Subjects With Endometrial Cancers. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Five Prime Therapeutics. | |||
| REF 3 | FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int J Nanomedicine. 2012; 7: 5915-5927. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.